SCHEMBL4752360

SCHEMBL4752360

CC1CCc2c(C(F)(F)F)n[nH]c2C1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
MAPK1 P28482 1/20 0.37
HDAC1 Q13547 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
AURKA O14965 1/20 0.33
ITK Q08881 1/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
CYP2A6 P11509 2/20 0.30
CYP2A13 Q16696 1/20 0.30
TSHR P16473 1/20 0.30
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26242997 1.00 CYP1A2 (0.42) CYP1A2CYP2C19LMNATP53MAPK1
SCHEMBL26255987 1.00 CYP1A2 (0.42) CYP1A2CYP2C19LMNATP53MAPK1
SCHEMBL4753322 0.87 CYP1A2 (0.46) CYP1A2CYP2C19LMNATP53MAPK1
SCHEMBL26858821 0.81 HDAC1 (0.34) LMNATP53MAPK1HDAC1HDAC8
SCHEMBL26251966 0.80 HCAR2 (0.42) HDAC1HDAC8HDAC6
SCHEMBL26251972 0.80 HCAR2 (0.42) HDAC1HDAC8HDAC6
SCHEMBL26242998 0.80 HCAR2 (0.42) HDAC1HDAC8HDAC6
SCHEMBL18325695 0.75 ALDH1A1 (0.37) LMNAAURKAITKALDH1A1HPGD
SCHEMBL26278118 0.73 RB1 (0.44) HDAC1HDAC8HDAC6ALDH1A1TSHR
SCHEMBL4753717 0.71 HCAR2 (0.44) LMNAHDAC1HDAC8HDAC6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023178181-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-09-21 WO disclosed
EP-4245756-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF Gilead Sciences, Inc. (US) 2023-09-20 EP disclosed
US-10202353-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2019-02-12 US disclosed
US-10202353-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2019-02-12 US disclosed
US-20160368881-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-12-22 US disclosed
US-20160368881-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-12-22 US disclosed
WO-2008148832-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEROF IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed
WO-2008148832-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEROF IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368881-A1 THERAPEUTIC COMPOUNDS HAVCR2, SARS1, RPL35 CYP1A2 782/4885CYP2C19 391/4885LMNA 3258/4885
US-10202353-B2 Therapeutic compounds RPL35, SARS1, HAVCR2 CYP1A2 903/4885CYP2C19 575/4885LMNA 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.